...
首页> 外文期刊>Journal of pediatric hematology/oncology: Official journal of the American Society of Pediatric Hematology/Oncology >Successful T-cell-depleted Haploidentical Hematopoietic Stem Cell Transplantation in a Child With Dyskeratosis Congenita After a Fludarabine-based Conditioning Regimen
【24h】

Successful T-cell-depleted Haploidentical Hematopoietic Stem Cell Transplantation in a Child With Dyskeratosis Congenita After a Fludarabine-based Conditioning Regimen

机译:基于氟达拉滨的调理方案后先天性角化不全儿童成功T细胞耗竭的单倍型造血干细胞移植。

获取原文
获取原文并翻译 | 示例
           

摘要

Allogeneic hematopoietic stem cell transplantation (HSCT) is the only cure for marrow failure associated with dyskeratosis congenita (DC). Data on transplants from alternative donors are limited. We describe a boy with DC and severe aplastic anemia who underwent haploidentical T-cell depleted HSCT using a reduced-intensity conditioning regimen. He underwent engraftment without toxicity or GVHD. His posttransplant course was complicated by EBV reactivation, treated with rituximab and EBV-specific T lymphocytes. After 26 months, he is in complete chimerism, with normal blood count and no sign of GVHD or pulmonary dysfunction. To the best of our knowledge, this is the first report of DC successfully treated with allogeneic HSCT from a haploidentical family donor.
机译:同种异体造血干细胞移植(HSCT)是治疗与先天性角化病相关的骨髓衰竭的唯一方法。来自替代供体的移植数据有限。我们描述了一个患有DC和严重再生障碍性贫血的男孩,该男孩使用降低强度的调理方案接受了单倍性T细胞耗竭的HSCT。他接受了移植,没有毒性或GVHD。用利妥昔单抗和EBV特异性T淋巴细胞治疗后,EBV激活使他的移植后病程复杂化。 26个月后,他处于完全嵌合状态,血液计数正常,没有GVHD或肺功能障碍的迹象。据我们所知,这是来自单倍体家庭供者的异基因HSCT成功治疗DC的首例报告。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号